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GOLD STAGE AND DURATION OF HOSPITAL ADMISSION DETERMINES 
SIZE AND STRUCTURE OF COPD RELATED DIRECT MEDICAL COSTS 
IN ELDERLY
Jakovljevic M1, Lazic Z2, Jankovic S1, Verhaeghe N3, Annemans L4
1The Medical Faculty University of Kragujevac, Kragujevac, Serbia; 2Clinical Center Kragujevac, 
Kragujevac, Serbia; 3Ghent University, Ghent, Belgium; 4Ghent University—Brussels 
University, Ghent, Belgium
OBJECTIVES: COPD cost of illness assessment and its dependence on GOLD stage 
or duration of hospital admission. METHODS: The sample consisted of 186 elderly 
COPD patients. Chest physicians conducted follow-up and ﬁ nancial data were 
obtained from administrative registry. Time horizon was one year and Health Insur-
ance Fund perspective was selected. Included clinical endpoints were disease exacerba-
tion and hospital admission. Economic data included all inpatient COPD-related 
medical goods and services consumption, and outpatient drug utilization. We excluded 
medical costs which did not arise from COPD. RESULTS: An average elderly COPD 
patient imposed c1745.41 of costs annually to the national health care budget. Severity 
grade (GOLD stage) and duration of all hospital admissions were signiﬁ cantly and 
directly correlated with overall cost. Expenses structure per year was: c14.54 outpa-
tient care, c126.97 inpatient drug consumption, c377.98 hospital admission (Intensive 
Care Unit admissions and specialist consultations included in daily price), c133.5 
imaging diagnostics, c111.43 laboratory analysis, c26.67 therapeutic interventions, 
c70.32 consumables, c884 outpatient drugs consumption. Most expenses originating 
from drug acquisition were due to antibiotics prescribed for curing infections and 
mucolitics and antihistamine drugs consumption. Average number of hospitalizations 
per person was 1.45 with a duration of 12.84 days. Fifteen persons deceased. Average 
number of outpatient visits was 2.71 per person. CONCLUSIONS: Overall burden 
of COPD is mostly driven by outpatient drug consumption and exacerbations leading 
to hospital admissions. Relative relevance of drug acquisition expenses in our country 
is higher than in high-income societies, because of still signiﬁ cantly lower human 
labour wages in the area. Pattern of diagnostic procedures requested and ATC drug 
classes consumed remains similar and comparable in most countries. More in-depth 
research of indirect COPD attributable costs e.g. lost productivity, absentism, prema-
ture death etc, will be needed in the future.
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PATTERNS AND COSTS OF HOSPITALIZATIONS IN ELDERLY 
PATIENTS IN RIO DE JANEIRO, BRAZIL
Takemoto ML, Fernandes RA, Passos RB, Tolentino ACM, Cukier FN, Takemoto MM, 
Moretti AIP
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OBJECTIVES: Ageing population implies greater demand of hospital services and 
consequent health care costs. This study aims to describe patterns of hospitalization 
and estimate hospitalization costs for aged patients in public hospitals in the city of 
Rio de Janeiro, Brazil. METHODS: Retrospective analysis of Rio de Janeiro hospital 
admissions for elderly people (aged ≥60 years) as reported in Brazilian Hospital 
Information System (SIH/DATASUS) database from January 1st to December 31st 
2007. The costs informed in the database represent federal reimbursement values for 
hospitalizations placed in public hospitals in the city. Admissions were categorized 
according to ICD-10 groups and age categories. RESULTS: 287,972 hospital admis-
sions were identiﬁ ed for all ages in the city in 2007 and 24.3% were for patients ≥60 
years (70,077). The ﬁ ve more common reasons for hospitalization were cardiovascular 
diseases (22.4%), cancer (17.5%), mental and cognitive disorders (11.2%), gastroin-
testinal (9.3%) and respiratory diseases (7.6%). The in-hospital mortality rate was 
14.76% for all causes. When disease groups were analyzed, infectious and respiratory 
diseases had the higher mortality rates (38.6% and 38.3%, respectively). The mean 
length of stay was 14.3 days and the average cost for elderly patients hospitalizations 
was 960,62 BRL. The total amount paid for hospitalization of elderly patients in 2007 
was 67,317,348 BRL, 30.7% of all hospitalization costs. CONCLUSIONS: The ﬁ nd-
ings showed the signiﬁ cant contribution of the elderly to public hospital expenditures 
with leading causes of admission including cardiovascular diseases, cancer and mental 
and cognitive disorders. Additionally, the higher in-hospital mortality rate was seen 
for preventable diseases. These results reinforce the need of prevention strategies 
among the elder population for targeted conditions.
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COST-BENEFIT OF FLUCONAZOLE FOR VAGINAL CANDIDIASIS
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OBJECTIVES: To perform cost-beneﬁ t analysis of ﬂ uconazole for VC in Russia. 
METHODS: Willingness-to-pay (WTP) for treatment of vaginal candidiasis was 
assessed. 240 women took part in the survey. a special questionnaire was designed to 
reveal women’s preferable methods of antifungal drug application and WTP for ﬂ u-
conazole in comparison with other drugs. Women were proposed: 1) to chose the 
preferable method of drug application; 2) to chose the preferable drug among 4 
options with similar efﬁ cacy but different methods of application and price (no con-
crete drug names were mentioned, only prices and costs of treatment and application 
methods); and 3) to give the maximal affordable price for treating vaginal candidiasis. 
RESULTS: More than 60% of women preferred oral treatment once with the mean 
costs of therapy 350 rubles ($11) among 4 proposed alternatives. The median WTP 
for antifungal therapy was 500 rubles ($16) (range from 50 to 5000 rubles, $1.6–
161.0) that is less than real cost of treatment with original ﬂ uconazole preparation. 
The cost-beneﬁ t ratio (WTP/cost of treatment) was 1.30 (range 0.09–20.6). CON-
CLUSIONS: Fluconazole is a cost-beneﬁ t alternative for VC treatment.
PIH15
ECONOMIC EVALUATION OF DARBEPOETIN ALFA (ARANESP) 
COMPARED TO EPOETIN ALFA (ERYPO) AND EPOETIN BETA 
(NEORECORMON) IN THE TREATMENT OF CHEMOTHERAPY-INDUCED 
ANEMIA (CIA) IN AUSTRIA
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OBJECTIVES: Anemia is a common side effect observed in patients receiving myelo-
suppressive chemotherapy [1]. The purpose of this pharmacoeconomic analysis was 
to evaluate the cost-effectiveness of the long-acting erythropoiesis-stimulating agent 
(ESA) darbepoetin alfa (DA) 500 mcg once every 3 weeks (Q3W) and 150 mcg weekly 
(QW), and short-acting ESAs epoetin-alfa (EA) 40,000 IU QW, epoetin-beta (EB) 
30,000 IU QW and 3-times weekly (TIW) for the treatment of CIA. METHODS: A 
cost-consequence model was constructed using a decision-analysis tree. The treatment 
period considered was based on 12 weeks and was aligned with routine chemotherapy 
regimen administration. Model inputs included: medical treatment, outcomes, and 
health care service utilization from published clinical trials and summary of product 
characteristics recommendation. Effectiveness of therapeutic alternatives was deter-
mined by comparing hemoglobin response rates. Costs included direct medical 
costs(intervention drug, inpatient and outpatient) and transportation costs. Costs 
presented reﬂ ect 2010 data. The analysis was performed from the perspective of the 
Austrian health care system. RESULTS: The average expected direct costs per patient 
were c3,675 for DA Q3W, c3830 for DA QW, c4290 for EA QW, c4240 for EB QW 
and c4745 for EB TIW. Cost-savings associated with DA Q3W were 4% relative to 
DA QW, 14% to EA QW, 13% to EB QW and 23% to EB TIW. The cost per hemo-
globin response rate (therapeutic success) amounted to c5035 for DA Q3W, c5247 
for DA QW, c6309 for EA QW, c6235 for EB QW and c6977 for EB TIW. CON-
CLUSIONS: In the treatment of CIA among cancer patients in Austria, darbepoetin 
alfa Q3W and QW are projected to provide more efﬁ cient use of health care resources 
compared to alternative treatment strategies such as epoetin-alfa and epoetin-beta. [1] 
Ludwig et al. Eur J Cancer 2004;40:2293–306.
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SURGICAL REPAIR OF ANTERIOR VAGINAL WALL PROLAPSE USING 
PROLIFT AND COLPORRHAPHY. A COST-EFFECTIVENESS ANALYSIS 
FOR A THIRD LEVEL HOSPITAL IN MEXICO
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OBJECTIVES: Estimate the clinical and economic outcomes of the surgical repair of 
anterior vaginal wall prolapse using Prolift® vs. colporrhaphy to assess its cost-
effectiveness under a third level hospital perspective in Mexico. METHODS: A multi-
state Markov model was developed to assess the evolution of a patient with anterior 
vaginal wall prolapse under a conventional surgical repair strategy (colporrhaphy) and 
a mesh grant (Prolift®) after 2, 4, 10 and 20 years. a specialist panel was conducted 
to collect current clinical practice, resource utilization and complication data. After 
the ﬁ rst surgical prolapse repair, the base-case patient could face two additional 
surgeries if prolapse relapsed. Two scenarios were modeled to compare the clinical 
and economic impact of Prolift® as second line treatment; the mesh grant was the 
assumed third line treatment for both scenarios. The effectiveness variable was the 
objective recurrence (failure) rate. Clinical data, transition probabilities and mortality 
rates were taken from published sources. Only direct medical costs were considered, 
and cost data was retrieved from IMSS ofﬁ cial cost list. The price of Prolift® was 
internally estimated. Results are expressed as 2010 inﬂ ation-adjusted Mexican pesos 
(MXN) and MXN/QALY for ICERs. a 4.5% discount rate was used for costs and 
outcomes. RESULTS: Total costs for year 1 were higher for the Prolift® strategy 
($75,688 vs. $74,544), but yielded an overall 22% complication reduction. For year 
2, total costs were lower for Prolift® ($81,675 vs. $104,007), yielding better outcomes 
(0.04 incremental QALYs), thus being a dominant strategy (−$528,682/QALY). For 
the following years, Prolift® showed to be a consistent cost-saving alternative vs. 
colporrhaphy: ICERs for years 4, 10 and 20 were −$273,598/QALY, −$29,942/QALY 
and −$1,212/QALY. CONCLUSIONS: Findings suggest Prolift® is a safe and cost-
effective alternative to treat anterior vaginal wall prolapse when compared to colpor-
rhaphy. Savings are due to lower failure and complication rates.
PIH17
COST-EFFECTIVENESS OF SEASONAL INFLUENZA VACCINATION IN 
PREGNANCY IS DEPENDENT ON VACCINATION EARLY IN FLU 
SEASON
Myers ER1, Misurski DA2, Swamy GK1
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OBJECTIVES: To estimate the impact of vaccination timing on the cost-effectiveness 
of seasonal inﬂ uenza vaccination in pregnancy for prevention of disease in women 
and infants under 6 months of age. METHODS: We constructed an open cohort 
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Markov simulation of US pregnant women and infants under 6 months of age for 1 
calendar year, from July 1 through June 30. National statistics on live births and infant 
mortality were used to generate probabilities of delivery and infant death based on 
gestational age. Each week, women entered the cohort with new pregnancies, and left 
by delivery; infants entered by delivery and left by death or reaching 6 months of age. 
Annual inﬂ uenza-attributable rates of outpatient visits and hospitalizations for preg-
nant women and infants were obtained from the literature, and adjusted to weekly 
incidences using CDC data on inﬂ uenza-positive respiratory isolates. In the base case, 
we assumed vaccination would begin in calendar week 40, be administered at routine 
prenatal visits across all gestational ages, and continue throughout the rest of the year, 
with vaccine efﬁ cacy of 73% for prevention of maternal ﬂ u and 63% for prevention 
of ﬂ u in infants under 6 months. Costs and maternal utilities were obtained from 
previously published analyses; we used published parental utilities for relevant infant 
health states. RESULTS: Base-case cost-effectiveness was $65,112/QALY gained. 
Fifty-six percent of the reduction in morbidity was attributable to prevention of disease 
in infants, and all of this beneﬁ t was accrued by vaccination within the ﬁ rst 4 weeks 
of vaccine availability. CONCLUSIONS: Vaccination of pregnant women against 
seasonal inﬂ uenza is cost-effective, with much of the beneﬁ t derived from prevention 
of infant disease. Vaccination is most efﬁ cient when the majority of pregnant women 
are vaccinated within 4 weeks of vaccine availability.
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COST-EFFECTIVENESS OF COMBINATION THERAPY WITH 
DUTASTERIDE AND TAMSULOSIN FOR THE TREATMENT OF 
MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA IN SPAIN
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Martín I6, Huerta A6
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OBJECTIVES: To evaluate the cost-effectiveness of the combination therapy with 
dutasteride and tamsulosin (D+T) as initiation treatment versus tamsulosin (T), con-
sidered the standard of care, in the treatment of moderate to severe benign prostatic 
hyperplasia (BPH) in Spain. METHODS: A semi-Markov model was developed using 
4-year and 35-year time horizons. Data were obtained from the CombAT and litera-
ture review, and the analysis was made from the National Healthcare Service perspec-
tive. Effectiveness was measured in terms of reduction of acute urinary retention 
(AUR) events and/or BPH-related surgeries and quality adjusted life-years (QALYs). 
Health care resources were deﬁ ned by an experts’ panel, and unitary costs were 
obtained from published Spanish sources and expressed in 2010 Euros. The model 
calculates costs, AURs and/or surgeries, and QALYs related to each therapy. Costs 
and effectiveness outcomes were discounted at 3.0%. One-way and probabilistic 
sensitivity analyses were conducted to test the robustness of the model. RESULTS: 
Combination therapy with D+T improves patients’ outcomes. At 4 years, D+T patients 
have a 9.9% reduction in AURs and/or surgeries over T, reaching 43.9% at 35 years. 
At 4 and 35 years, total costs related to T treatment add up to 1,373.90c and 
5,187.37c, and total costs related to D+T are 2,184.43c and 8,630.99c, respectively. 
Therefore, at 4 years, treatment with D+T presents an additional cost of 81.66c per 
AUR and/or surgery avoided and 14,023.32c per QALY gained compared to T. At 
35 years, results were 79.10c per AUR and/or surgery avoided and 8,750.15c per 
QALY gained. Sensitivity analyses showed that results are robust. CONCLUSIONS: 
Given the assumptions, combination treatment with D+T not only represents a more 
effective alternative versus T due to the reduction in AURs and/or surgeries, but also 
is a cost-effective treatment in patients with moderate to severe BPH in Spain.
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TRENDS IN COST-EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT 
DRUGS
Aggarwal S1, Stevens CA2
1PAREXEL Consulting, Bethesda, MD, USA; 2PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost-effectiveness studies for the top 10 highest selling drugs (~$80–95B worldwide 
sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. 
For this analysis, we segmented these drugs into categories as primary care, specialty, 
small molecules, biologics, therapy areas and availability of generic alternatives. We 
analyzed the cost-effectiveness studies that were published in peer-reviewed journals. 
Search was conducted using generic names of the drugs and the phrase “cost-effec-
tiveness” in abstract of the published study. RESULTS: During 2003–2008, the 
number of published studies on “cost-effectiveness” have increased by more than 
30%. Almost half of the published studies belong to—Remicade, Plavix and Enbrel. 
There is a large variability in CERs for same drugs for different indications, in some 
cases also varying by biomarkers. Primary care drugs had lower and less variable CERs 
than specialty drugs. Variations also exist in methodology used by different groups in 
modeling cost-effectiveness, especially for time horizon and comparator. Majority of 
primary care drugs were modeled for a time horizon of 35–40 years or lifetime to 
demonstrate cost-effectiveness. Among the top 10 drugs, quetiapine and erythropoi-
etin had the highest variability across different studies, and atorvatstatin, salmetrol/
ﬂ uticasone and clopidogrel had the most consistent ICER values across studies. CON-
CLUSIONS: This analysis shows the range, variability and methods used for calcula-
tion of ICER values for these high budget impact drugs and provides lessons for 
executives and policy makers.
PIH20
EXPLORATORY COST-EFFECTIVENESS ANALYSIS OF THE ANTERIOR 
REPAIR OF THE PELVIC ORGAN PROLAPSE COMPARING ANTERIOR 
COLPORRHAPHY (CONVETIONAL SURGERY) VERSUS PROLIFT® MESH, 
UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
Nasciben V
Johnson & Johnson, Sao Paulo-SP, Brazil
OBJECTIVES: To assess the cost-effectiveness of the anterior repair of the Pelvic organ 
prolapse (POP) with Prolift® versus the colporrhaphy (COLP), under private payer 
perspective, in Brazil. METHODS: A multi-state Markov model was developed to 
assess the evolution of a patient with anterior vaginal prolapse after COLP and 
Prolift® after 2, 4, 10 and 20 years. a panel of specialist was conducted to obtain the 
local practice and to collect the complication rates. Only direct medical costs were 
considered (SIMPRO, 2010; CBHPM 5th Ed). Clinical data, transition probabilities 
and mortality rates were taken from published sources (IBGE, 2008; Jia, X 2007). 
The base-case patient could face up to three surgical repairs if prolapse relapsed. Two 
scenarios were modeled to compare the clinical and economic impact of Prolift® as 
second line treatment; mesh grant was the assumed third line treatment for both 
scenarios. Discount rate of 5% for costs and outcomes was taken following the Brazil-
ian HTA guidelines (Vianna, 2007). One-way sensitivity analysis was conducted to 
assess the robustness of the results. RESULTS: The total costs for the ﬁ rst year were 
higher for Prolift® (R$8119 versus R$4777; incremental R$3342). For the 2nd year 
the difference in the total costs reduced (R$8659 vs. R$7435; additional R$1223) 
with better outcomes for Prolift® (incremental QALYs: 0.04) with ICER ranging from 
R$19,099 (non discounted) to R$33,207 (discounted). For the next years the ICERs 
reduced, showing long term beneﬁ ts of the adoption of Prolift®. For the fourth year 
ICER ranging from R$419 to R$532, 10th year from R$578 to R$827 and for the 
20th year ranging from R$832 to R$1291, for non discounted and discounted results. 
CONCLUSIONS: Findings suggest Prolift® as a cost-effective intervention, under the 
Brazilian private payer perspective.
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IS ROUTINE IMMUNIZATION OF ELDERLY WITH THE 13-VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE LIKELY TO BE CONSIDERED 
AS COST-EFFECTIVE?
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OBJECTIVES: To estimate the cost-effectiveness in relation to the efﬁ cacy of PCV-13 
among elderly (both the total population and those at increased risk) aged 65 years 
and older for the The Netherlands, for various levels of efﬁ cacy assumed. METHODS: 
Our previously published cost-effectiveness model was updated to include, age-speciﬁ c 
epidemiological data and health care utilization and costs for a hypothetical cohort 
of elderly aged over 65 years of the population of the The Netherlands. This cohort 
was followed twice- once as unvaccinated and once as a vaccinated cohort- over a 
time period of 5 years. Outcome measures included costs, life-years (LYs), quality-
adjusted life-years (QALYs) and cost-effectiveness ratios (CERs). All analyses were 
performed from a societal perspective. RESULTS: Vaccination remained well below 
the c80,000 per LY except if the vaccine was only assumed to be protective against 
bacteraemic pneumonia with a relatively low effectiveness (40%) in combination with 
a high vaccine price (c65) and indirect effects of serotype replacement would largely 
offset the direct effect of vaccination. For various assumptions, introduction PCV-13 
(assuming a 60% efﬁ cacy against invasive and non invasive disease due to vaccine 
serotypes, and a cost of c50 per vaccinated person) the incremental cost-effectiveness 
ratio varies over from cost-saving to c50,676 per LY. More probable scenarios gener-
ated cost-effectiveness ratios which would be labeled as cost-effective. CONCLU-
SIONS: In the The Netherlands, vaccination with PCV-13 is likely to be considered 
cost-effective both for the total and for the high-risk population over 65 years of age 
from a societal perspective over a ﬁ ve-year time horizon. The main limitation of this 
study was the uncertainty regarding the share of pneumococcal related pneumonia.
PIH22
EVALUATING THE COST-EFFECTIVENESS OF CERVICAL CANCER 
SCREENING AND HUMAN PAPILLOMAVIRUS VACCINATION 
STRATEGIES USING A MATHEMATICAL MODEL
Taylor DC1, Pawar V1, Gilmore K1, Sanon M1, Kruzikas D2, Kohli M3, Arondekar B4, 
Demarteau N5, Weinstein M6
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OBJECTIVES: To assess the cost-effectiveness of various cervical screening strategies 
in a cohort of 12-year-old US women with (V) and without (NV) a human papillo-
mavirus (HPV) 16/18 vaccine with efﬁ cacy against vaccine and non-vaccine oncogenic 
HPV types. METHODS: A lifetime Markov model simulating the progression of HPV 
infection and subsequent cervical disease (cervical intraepithelial neoplasia (CIN), 
